MJFF grants supports Lysoway’s TMEM175 agonist program
Summary
Lysoway Therapeutics received an additional research grant from The Michael J. Fox Foundation for Parkinson’s Research. The funding will support development of the company’s TMEM175 agonist program for Parkinson’s disease. This is a small research-support announcement rather than a product, acquisition, or leadership update. The item is relevant to readers tracking biotech financing activity and development-stage life sciences companies.
Funding
Amount
None
Total raised
Date
June 2, 2026
Announcement date
Investors
The Michael J. Fox Foundation
Lead investors
Company
lysoway.com
Funded company
Classifications
industries
No industries detected
applications
No applications detected
AskAI Classifications
Labels
No AI classifications detected